Fidelity International’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.97M | Sell |
65,946
-29,068
| -31% | -$2.44M | ﹤0.01% | 678 |
|
|
2026
Q1 | $7.61M | Buy |
95,014
+34,626
| +57% | +$2.85M | 0.01% | 631 |
|
|
2025
Q4 | $5.15M | Buy |
60,388
+11,846
| +24% | +$972K | ﹤0.01% | 652 |
|
|
2025
Q3 | $3.78M | Buy |
48,542
+45,062
| +1,295% | +$3.52M | ﹤0.01% | 672 |
|
|
2025
Q2 | $272K | Buy |
+3,480
| New | +$260K | ﹤0.01% | 834 |
|
|
2024
Q4 | – | Sell |
-19,257
| Closed | -$1.27M | – | 934 |
|
|
2024
Q3 | $1.27M | Sell |
19,257
-484
| -2% | -$35.2K | ﹤0.01% | 717 |
|
|
2024
Q2 | $1.82M | Buy |
+19,741
| New | +$1.75M | ﹤0.01% | 691 |
|
|
2023
Q4 | – | Sell |
-7,793
| Closed | -$540K | – | 825 |
|
|
2023
Q3 | $540K | Buy |
7,793
+6,738
| +639% | +$541K | ﹤0.01% | 717 |
|
|
2023
Q2 | $99.5K | Buy |
+1,055
| New | +$91.7K | ﹤0.01% | 741 |
|
|
2021
Q2 | – | Sell |
-16
| Closed | -$1K | – | 924 |
|
|
2021
Q1 | $1K | Sell |
16
-2,435
| -99% | -$206K | ﹤0.01% | 900 |
|
|
2020
Q4 | $224K | Buy |
2,451
+2,433
| +13,517% | +$202K | ﹤0.01% | 720 |
|
|
2020
Q3 | $1K | Buy |
18
+6
| +50% | +$468 | ﹤0.01% | 863 |
|
|
2020
Q2 | $1K | Hold |
12
| – | – | ﹤0.01% | 836 |
|
|
2020
Q1 | $1K | Sell |
12
-9
| -43% | -$649 | ﹤0.01% | 770 |
|
|
2019
Q4 | $2K | Sell |
21
-3
| -13% | -$234 | ﹤0.01% | 814 |
|
|
2019
Q3 | $2K | Buy |
24
+6
| +33% | +$421 | ﹤0.01% | 767 |
|
|
2019
Q2 | $1K | Hold |
18
| – | – | ﹤0.01% | 821 |
|
|
2019
Q1 | $1K | Sell |
18
-3
| -14% | -$171 | ﹤0.01% | 803 |
|
|
2018
Q4 | $1K | Sell |
21
-9
| -30% | -$455 | ﹤0.01% | 800 |
|
|
2018
Q3 | $2K | Buy |
+30
| New | +$1.47K | ﹤0.01% | 767 |
|
|
2018
Q2 | – | Sell |
-72,378
| Closed | -$3.37M | – | 679 |
|
|
2018
Q1 | $3.37M | Sell |
72,378
-61,833
| -46% | -$2.69M | 0.01% | 424 |
|
|
2017
Q4 | $5.04M | Hold |
134,211
| – | – | 0.01% | 411 |
|
|
2017
Q3 | $4.89M | Hold |
134,211
| – | – | 0.01% | 403 |
|
|
2017
Q2 | $5.29M | Sell |
134,211
-10,065
| -7% | -$367K | 0.02% | 391 |
|
|
2017
Q1 | $4.52M | Hold |
144,276
| – | – | 0.01% | 417 |
|
|
2016
Q4 | $4.51M | Buy |
144,276
+58,971
| +69% | +$1.91M | 0.01% | 408 |
|
|
2016
Q3 | $3.43M | Hold |
85,305
| – | – | 0.01% | 419 |
|
|
2016
Q2 | $2.84M | Sell |
85,305
-259,827
| -75% | -$8.89M | 0.01% | 429 |
|
|
2016
Q1 | $10.1M | Hold |
345,132
| – | – | 0.03% | 331 |
|
|
2015
Q4 | $9.09M | Sell |
345,132
-1,031,322
| -75% | -$26.8M | 0.03% | 337 |
|
|
2015
Q3 | $32.6M | Sell |
1,376,454
-43,020
| -3% | -$1.04M | 0.11% | 186 |
|
|
2015
Q2 | $33.7M | Sell |
1,419,474
-184,854
| -12% | -$4.17M | 0.11% | 182 |
|
|
2015
Q1 | $38.1M | Buy |
1,604,328
+77,028
| +5% | +$1.73M | 0.12% | 167 |
|
|
2014
Q4 | $32.4M | Sell |
1,527,300
-996,048
| -39% | -$20M | 0.11% | 181 |
|
|
2014
Q3 | $43M | Buy |
2,523,348
+1,802,136
| +250% | +$28.4M | 0.16% | 140 |
|
|
2014
Q2 | $10.3M | Buy |
+721,212
| New | +$9.78M | 0.04% | 339 |
|
Other funds holding EW
VCM
VPM
Fidelity International's EW Position: Q2 2026 in Review
Fidelity International reduced its Edwards Lifesciences (EW) stake by 31% in Q2 2026, selling an estimated $2.44M and leaving 65,946 shares worth $5.97M. The position accounts for ﹤0.01% of the portfolio, ranked #678.
Fidelity International first reported a position in EW in Q2 2014 and has held it in 36 quarters since. The position peaked at $43M in Q3 2014. 1,168 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Fidelity International held 65,946 shares of Edwards Lifesciences worth $5.97M as of Q2 2026.
- Fidelity International sold 29,068 Edwards Lifesciences shares in Q2 2026, an estimated $2.44M.
- Edwards Lifesciences made up ﹤0.01% of Fidelity International's portfolio in Q2 2026, its #678 holding.
- Fidelity International first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 36 quarters since.
- Fidelity International's Edwards Lifesciences position peaked at $43M in Q3 2014.
- 1,168 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.